Peptide Library

Human study PLS-00168

MALDI-imaging reveals thymosin beta-4 as an independent prognostic marker for colorectal cancer.

Other design · Not reported participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • MALDI-imaging reveals thymosin beta-4 as an independent prognostic marker for colorectal cancer.primary · Oncotarget · 2015-12-01 · PMID 26556858 · DOI

Design and participants

Design
Other design
Population
Colon cancer tissue samples (diploid and aneuploid carcinoma) and normal colonic mucosa, plus a tissue microarray of clinical samples from colon cancer patients
Conditions
Colorectal cancer
Planned enrollment (registry)
Not reported
Enrolled
Not reported
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): MALDI imaging identified a peak as thymosin beta-4, which distinguished ploidy status and was validated on a tissue microarray as a predictor of overall survival in colon cancer patients.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Tβ4 was measured only as an endogenous tissue biomarker. It was never administered, so the study gives no evidence on treatment effects or safety.
    • abstract only: Only the PubMed abstract is available in the record. It gives no sample sizes or effect estimates.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 26556858, abstract (sentences 7-8) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 26556858, abstract (sentences 3-5) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 26556858, abstract (sentences 3 and 8) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).